Total Payments
$6,951
2024 Payments
$462.48
Companies
38
Transactions
246
Medicare Patients
10,806
Medicare Billing
$1.0M
Payment Breakdown by Category
Food & Beverage$6,747 (97.1%)
Education$204.26 (2.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,747 | 243 | 97.1% |
| Education | $204.26 | 3 | 2.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $721.25 | 18 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $635.66 | 34 | $0 (2024) |
| GlaxoSmithKline, LLC. | $617.08 | 5 | $0 (2022) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $555.72 | 32 | $0 (2024) |
| Amgen Inc. | $415.45 | 14 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $376.00 | 9 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $370.78 | 16 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $365.22 | 15 | $0 (2023) |
| Astellas Pharma US Inc | $326.38 | 8 | $0 (2023) |
| Merck Sharp & Dohme LLC | $247.09 | 12 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $462.48 | 26 | Novartis Pharmaceuticals Corporation ($201.24) |
| 2023 | $766.56 | 38 | Novartis Pharmaceuticals Corporation ($187.05) |
| 2022 | $1,176 | 35 | Astellas Pharma US Inc ($210.97) |
| 2021 | $1,106 | 36 | Boehringer Ingelheim Pharmaceuticals, Inc. ($141.98) |
| 2020 | $664.01 | 24 | Abbott Laboratories ($306.59) |
| 2019 | $926.79 | 31 | Braemar Manufacturing, LLC ($229.07) |
| 2018 | $750.51 | 19 | Boehringer Ingelheim Pharmaceuticals, Inc. ($138.99) |
| 2017 | $1,099 | 37 | AstraZeneca Pharmaceuticals LP ($189.75) |
All Payment Transactions
246 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $9.40 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/05/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $45.67 | General |
| Category: Cardiac Rhythm Management | ||||||
| 07/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.19 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/29/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: Cardiology | ||||||
| 05/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/20/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.44 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 05/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/23/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/14/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $32.98 | General |
| Category: Cardiology | ||||||
| 04/10/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: DIABETES | ||||||
| 03/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/13/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $1.42 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $22.93 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/22/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/22/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $3.13 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/14/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $26.24 | General |
| Category: Medical Device | ||||||
| 02/07/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $20.22 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/05/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Not Applicable | ||||||
| 01/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/18/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: Cardiovascular & Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 34 | 2,668 | 5,882 | $726,279 | $288,506 |
| 2022 | 31 | 2,501 | 4,407 | $562,938 | $235,108 |
| 2021 | 33 | 2,968 | 5,218 | $648,185 | $273,842 |
| 2020 | 33 | 2,669 | 4,464 | $555,414 | $223,258 |
Total Patients
10,806
Total Services
19,971
Medicare Billing
$1.0M
Procedure Codes
135
All Medicare Procedures & Services
135 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 442 | 1,008 | $108,864 | $70,184 | 64.5% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 143 | 1,014 | $107,484 | $42,208 | 39.3% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 126 | 785 | $103,620 | $35,792 | 34.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 187 | 192 | $105,600 | $31,883 | 30.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 40 | 40 | $44,920 | $16,056 | 35.7% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 130 | 444 | $38,184 | $14,892 | 39.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 75 | 75 | $26,400 | $12,621 | 47.8% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 57 | 57 | $28,899 | $9,708 | 33.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 117 | 119 | $35,292 | $6,395 | 18.1% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 40 | 80 | $12,000 | $6,097 | 50.8% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 34 | 136 | $14,586 | $5,666 | 38.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 41 | 75 | $9,012 | $4,818 | 53.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 40 | $6,120 | $3,823 | 62.5% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 12 | 311 | $8,086 | $2,806 | 34.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 50 | 50 | $11,250 | $2,733 | 24.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 184 | 222 | $12,432 | $2,663 | 21.4% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 108 | 139 | $6,533 | $2,288 | 35.0% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 30 | 49 | $4,361 | $2,202 | 50.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $4,560 | $2,143 | 47.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 139 | 241 | $1,928 | $1,889 | 98.0% |
| 83880 | Natriuretic peptide (heart and blood vessel protein) level | Office | 2023 | 38 | 48 | $4,560 | $1,847 | 40.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 111 | 137 | $4,110 | $1,418 | 34.5% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 81 | 81 | $3,078 | $1,340 | 43.5% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 20 | 21 | $7,392 | $1,293 | 17.5% |
| 93289 | Evaluation of single, dual, or multiple lead implantable defibrillator system | Office | 2023 | 13 | 19 | $2,584 | $1,126 | 43.6% |
About Dr. Thomas Young, MD
Dr. Thomas Young, MD is a Interventional Cardiology healthcare provider based in San Diego, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104998194.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Young, MD has received a total of $6,951 in payments from pharmaceutical and medical device companies, with $462.48 received in 2024. These payments were reported across 246 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($6,747).
As a Medicare-enrolled provider, Young has provided services to 10,806 Medicare beneficiaries, totaling 19,971 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 135 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Cardiology
- Location San Diego, CA
- Active Since 11/14/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RI0011X
- Entity Type Individual
- NPI Number 1104998194
Products in Payments
- LifeVest (Device) $555.72
- Repatha (Biological) $385.84
- ENTRESTO (Drug) $331.62
- ELIQUIS (Drug) $318.56
- LEQVIO (Drug) $304.04
- Xience Sierra Coronary Stent (Device) $257.58
- XARELTO (Drug) $251.18
- TRELEGY ELLIPTA (Drug) $248.64
- BRILINTA (Drug) $241.37
- Cardiac Monitoring Suite (Device) $229.07
- VERQUVO (Drug) $223.24
- JARDIANCE (Drug) $201.02
- MULTAQ (Drug) $162.72
- WATCHMAN (Device) $140.29
- Optimizer (Device) $136.53
- BYDUREON (Drug) $123.85
- ANORO (Drug) $121.84
- ANORO ELLIPTA (Drug) $121.79
- INVOKANA (Drug) $119.60
- RYBELSUS (Drug) $118.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Interventional Cardiology Doctors in San Diego
Dr. Justin Cox, M.d, M.D
Interventional Cardiology — Payments: $381,323
Interventional Cardiology $381,323
Dr. Arvin Narula, Md, MD
Interventional Cardiology — Payments: $128,097
Interventional Cardiology $128,097
Dr. Belal Al Khiami, Md, MD
Interventional Cardiology — Payments: $24,593
Interventional Cardiology $24,593
Dr. Ajay Yadlapati, M.d, M.D
Interventional Cardiology — Payments: $23,274
Interventional Cardiology $23,274
Dr. Ryan Reeves, Md, MD
Interventional Cardiology — Payments: $22,973
Interventional Cardiology $22,973
Dr. Jeffrey Cavendish, Md, MD
Interventional Cardiology — Payments: $17,446
Interventional Cardiology $17,446